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ABSTRACT
Objective: Indicators of potentially preventable
hospitalisations have been adopted internationally as a
measure of health system performance; however, few
assess appropriate processes of care around
medication use, that if followed may prevent
hospitalisation. The aim of this study was to develop
and validate evidence-based medication-related
indicators of potentially preventable hospitalisations.
Setting: Australian primary healthcare.
Participants: Medical specialists, general practitioners
and pharmacists. A modified RAND appropriateness
method was used for the development of medication-
related indicators of potentially preventable
hospitalisations, which included a literature review,
assessment of the strength of the supporting evidence
base, an initial face and content validity by an expert
panel, followed by an independent assessment of
indicators by an expert clinical panel across various
disciplines, using an online survey.
Primary outcome measure: Analysis of ratings was
performed on the four key elements of preventability;
the medication-related problem must be recognisable,
the adverse outcomes foreseeable and the causes and
outcomes identifiable and controllable.
Results: A total of 48 potential indicators across all
major disease groupings were developed based on
level III evidence or greater, that were independently
assessed by 78 expert clinicians (22.1% response
rate). The expert panel considered 29 of these (60.4%)
sufficiently valid. Of these, 21 (72.4%) were based on
level I evidence.
Conclusions: This study provides a set of face and
content validated indicators of medication-related
potentially preventable hospitalisations, linking
suboptimal processes of care and medication use with
subsequent hospitalisation. Further analysis is required
to establish operational validity in a population-based
sample, using an administrative health database.
Implementation of these indicators within routine
monitoring of healthcare systems will highlight those
conditions where hospitalisations could potentially be
avoided through improved medication management.
INTRODUCTION
Clinical indicators of potentially preventable
hospitalisations are used as a measure of
health system performance and quality of
healthcare provided to patients.1 2 Potentially
preventable hospitalisations are defined as
those hospitalisations that could be prevented
with the provision of timely and effective
primary care.3 Medication-related hospitalisa-
tions are relatively common. A literature
review found that 2–3% of all hospital admis-
sions in the Australian healthcare setting were
medication related, with half considered to be
potentially preventable.4 A systematic review of
studies from around the world found that a
median of 3.7% of all hospital admissions were
preventable medication-related admissions.5
The identification and subsequent reduction
of the most common medication-related
potentially preventable hospitalisations will
improve morbidity and quality of life for
patients, safety of the healthcare system and
reduce healthcare expenditure.
Clinical indicators of medication-related
potentially preventable hospitalisations have
been developed which link suboptimal
Strengths and limitations of this study
▪ The clinical indicators developed were based on
high-level evidence together with expert clinical
panel assessment.
▪ Since the clinical indicators were developed
using Australian-specific resources they may
need to be adapted for use in other settings.
▪ This study provides a set of face and content
validated indicators of potentially preventable
hospitalisations, linking to suboptimal processes
of care and medication use with subsequent
hospitalisation.
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processes of care with medicine use to assess adverse
outcomes including hospitalisation.2 6–8 The overall inci-
dence of preventable medication-related hospitalisations
when measured using these clinical indicator sets has
been reported to range between 3% and 20%, depend-
ing on the country of the study population and the clin-
ical indicator set used.9–11 Using the previously
developed clinical indicators, the prevalence of poten-
tially preventable medication-related hospitalisations in
the Australian healthcare setting between 1 January
2004 and 31 December 2008 was examined. During the
5-year study period there were 44 416 (20.5%) poten-
tially preventable medication-related hospitalisations,
equating to 9000 preventable admissions each year.11
However, in undertaking the study, it became apparent
that many of the internationally developed indicators
were not relevant or applicable to the Australian health-
care setting. A cross-country comparison between the
USA and the UK indicators found that of the 46 indica-
tors assessed, 58% were relevant to the USA but not the
UK, and only 41% were deemed to be relevant in the
healthcare setting of both countries.8 Given the signifi-
cant differences between the USA and the UK health-
care systems to that of Australia, there may be additional
indicators, specifically relevant to the Australian health-
care system, that should be examined. Further, the inter-
national indicators were developed over 10 years ago
and there are likely to be a number of indicators based
on new medicines introduced since then.
Prior studies which developed clinical indicators for
potentially preventable medication-related hospitalisations
used the Delphi technique,2 6 8 12 13 which measures con-
sensus among experts using a series of structured
surveys.14 15 Recent studies have highlighted the need for
clinical indicators to be evidence based, rather than based
on expert consensus only.11 13 16 Increasingly, the RAND
appropriateness method is used in indicator develop-
ment,17 18 which develops indicators by combining
evidence-based recommendations from clinical guidelines
with expert clinical opinion. In addition, recent studies
have highlighted the need for clinical indicators to be
country specific to reflect current practice within individ-
ual healthcare systems.11 13 16 To date, no evidence-based
indicators of medication-related potentially preventable
hospitalisations have been developed specific for the
Australian setting. The aim of this study was to develop
and validate Australian evidence-based medication-related
indicators of potentially preventable hospitalisations.
METHODS
A modified RAND appropriateness method was used for
the development of medication-related indicators of
potentially preventable hospitalisations, which has
characteristics of both the Delphi and Nominal Group
Techniques, providing a systematic method to combine
evidence with expert opinion.19 It consists of a literature
review, assessment of the strength of the supporting
evidence base, an initial face and content validity assess-
ment by an expert panel, followed by an independent
assessment of indicators by an expert clinical panel
across various disciplines, using an online survey.
Identification of existing indicators and development
of new indicators
A number of methods were used to systematically iden-
tify and develop clinical indicators for medication-
related potentially preventable hospitalisations, specific
for the Australian healthcare setting. A literature review
was conducted to identify all published studies of indica-
tors for preventable medication-related hospitalisations
that could be adapted using specific inclusion criteria.
Identification and development of additional clinical
indicators was based on chronic diseases included in
Australia’s National Health Priority Areas.20 In addition,
indicators were developed for gastrointestinal disorders,
which are associated with high prevalence and morbidity
in Australia.21 Australian treatment and clinical guide-
lines for these chronic conditions were then examined
to identify potential mediation-related issues relevant for
the development of clinical indicators for preventable
medication-related hospitalisations.
Literature review to identify existing clinical indicators of
potentially preventable medication-related hospitalisations
A literature review of all published studies on clinical
indicators for preventable medication-related hospitalisa-
tions was conducted from January 2001 to December
2012, inclusive. The primary search terms used were
‘indicators’, ‘prevent$ OR avoid$’, ‘medication OR
drug-related’, ‘hospitalisation OR morbidity’ and
‘adverse drug event’. MEDLINE (via Ovid) and
EMBASE were searched, with results limited to articles
published in English and conducted in adults. Studies
which developed indicators not associated with the
outcome of hospitalisation were excluded. Reference
lists of relevant identified studies were further searched
to identify additional papers. The following information
was extracted from each suitable study: the hospitalisa-
tion outcome, the process of care leading to the
outcome and references (ie, studies which developed
the indicator). Clinical indicators were grouped accord-
ing to broader chronic disease groupings and similar
clinical indicators obtained from different studies were
recorded as one clinical indicator.
Predefined inclusion criteria were used to determine
the applicability and relevance of previously published
clinical indicators to the Australian healthcare setting.
Indicators that did not meet one or more of these cri-
teria were excluded from the study.
The inclusion criteria were the following:
1. Strength of supporting evidence must be Grade B or
level III or higher, based on the National Health and
Medical Research Council (NHMRC) evidence matrix.22
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2. The medicine must be available in Australia and sub-
sidised under the Schedule of Pharmaceutical
Benefits (PBS or RPBS).23
3. The process of care must concur with Australian
treatment guidelines.
4. The process of care can be identified in Australian
electronic health records.
Concordance of the indictors with current Australian
treatment and clinical guidelines were identified from
the Australian Therapeutic Guidelines,24 Australian
Medicines Handbook25 and clinical guidelines including
cardiovascular disease,26–30 respiratory conditions,31 32
diabetes,33 34 musculoskeletal conditions35 36 and
mental health.37 38 Where the international clinical indi-
cators differed slightly from Australian guidelines, modi-
fications were developed if appropriate. The guidelines
were also searched to determine the level of supporting
evidence. The strength of the supporting evidence for
each indicator was assessed and categorised into five
levels based on current Australian standards, used for
guideline development.39 Only those indicators with
level III or greater evidence were included. The WHO
International Classification of Diseases (ICD) 10–AM
classification was used to identify codes for hospitalisa-
tion outcomes.40
Development of new clinical indicators of potentially
preventable medication-related hospitalisations
Development of new clinical indicators was largely based
on those chronic diseases included in Australia’s
National Health Priority Areas.20 Chronic obstructive
pulmonary disease was included with asthma under the
broad disease category of respiratory conditions due to
its large disease burden and mortality.41 Gastrointestinal
disorders which are associated with high prevalence and
morbidity in Australia, were also included.21 Clinical
indicators for cancer were not developed in this study.
Medicine use for cancer is highly specialised and varied
depending on the type of cancer, and the development
of new medicines for these conditions is a fast evolving
area. To develop new indicators treatment and clinical
guidelines for each of the conditions were reviewed,
with a focus on treatment considerations, medicine class
statements and monographs, contraindications, precau-
tions, recommended testing and follow-up. All newly
developed indicators were required to meet the inclu-
sion criteria used for previously published clinical indi-
cators, as described above.
Initial face and content validity by a convenience sample
of pharmacists
An initial face and content validity of the compiled list
of indicators was undertaken with a convenience sample
of eight clinical pharmacists. Based on the four elements
of preventability developed by Hepler and Strand,42 they
were asked the following questions: would you expect
most health professionals to
1. Recognise the problem in the process of care?
2. Foresee the potential for hospitalisation associated
with the process of care?
3. Know how to change the process of care to reduce
the likelihood of hospitalisation?
4. Be able to change the process of care to reduce the
likelihood of hospitalisation?
Responses to each of the four elements of preventabil-
ity were rated on a three-point Likert scale, where ‘1’
indicates disagreement, ‘2’ uncertain or equivocal and
‘3’ agreement, together with comments to allow for
feedback or suggestions regarding specific elements or
readability. For each indicator, a majority agreement
(5/8 or 62.5%) by the convenience sample across all
four elements of preventability was required for inclu-
sion in our final list for validation by an expert panel.
Expert panel assembly, survey and analysis
The final list of indicators for validation were grouped
into subject categories (cardiovascular disease, diabetes,
renal, mental health, respiratory, gastrointestinal and
osteoporosis/fracture indicators) and sent to clinical
experts for review. Experts were identified as clinical
leaders in their field, that included both medical physi-
cians (general practitioners and specialists) and pharma-
cists (including certified geriatric pharmacists and
clinical pharmacists), across Australia from a range of
healthcare settings. A total of 352 clinical experts were
identified and contacted to be part of the expert clinical
panel for validation of the indicators, between December
2012 and March 2013. They were invited to score the
indicators using an online survey (SurveyMonkey http://
www.surveymonkey.com) on the four elements of prevent-
ability, as described above. Participants were not able to
respond to the survey more than once. A brief summary
of each indicator was provided; the level of evidence for
each indicator together with the reference(s) supporting
the level of evidence. A priori criteria of consensus for
validation for each of the indicators were defined; an
average score of 70% or greater agreement by the expert
panellists, across all four elements of preventability for
each indicator, were deemed to meet requirements for
validation of an indicator. As described above, responses
to each of the four elements of preventability were rated
on a three-point Likert scale, where ‘1’ indicates disagree-
ment, ‘2’ uncertain or equivocal and ‘3’ agreement,
together with comments to allow for feedback on each of
the individual indicators.
RESULTS
A total of 48 potential indicators across major disease
groupings based on level III evidence or greater were
developed (table 1), all of which had majority agree-
ment in the initial face and content validity by a conveni-
ence sample of eight clinical pharmacists. Of these, 13
were from previously developed medication-related indi-
cators of potentially preventable hospitalisations, 15 were
modified to be applicable to the Australian healthcare
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Table 1 Australian medication-related potentially preventable hospitalisation clinical indicator set
Number
Hospitalisation












1. History of MI (in 2 years prior to admission)
2. Not on aspirin, β-blocker, ACEI or ARB and statin (in




Changed outcome from just




1. Patient has coronary artery stent (in 1 year prior to
admission)
2. No use of aspirin or clopidogrel (in 12 months prior to
admission)
Level I28 28
3 CHF 1. History of CHF (in 2 years prior to admission)
2. Not on an ACEI or ARB (in 3 months prior to admission)
Level I26 Added ARB for those
intolerant to ACEI6–8
4 CHF 1. History of CHF (in 2 years prior to admission)
2. Not on a heart failure indicated β-blocker (in 3 months
prior to admission)
Level I26 26
5 CHF 1. History of CHF
2. Use of rosiglitazone or pioglitazone (in 6 months prior to
admission)
Level I33 33
6 CHF 1. History of CHF
2. Use of NSAID (in 3 months prior to admission)
Level I49 Removed fluid overload
from outcome2 6–8
7 CHF or cardiac
ischaemic event
1. History of IHD (in 2 years prior to admission)
2. Use of rosiglitazone (in 6 months prior to admission)
Level I50 33
8 CHF and / or heart block 1. History of CHF with heart block or advanced bradycardia
(in 2 years prior to admission)
2. Use of digoxin (in 6 months prior to admission)
Level III51 6–8
9 CHF or MI 1. Concurrent use of insulin and rosiglitazone Level III50 33
10 Ischaemic stroke 1. History of chronic AF or ischaemic stroke in 2 years prior
to admission)
2. No use of warfarin or aspirin (in 3 months prior to
admission)
Level I30 8
11 VTE or stroke 1. History of coronary artery disease or VTE
2. Use of raloxifene
Level II52 35
Mental health indicators
12 Bipolar disorder 1. History of bipolar disorder
2. Use of lithium
3. Drug level not monitored in the previous 3 months
Level I38 6 7
13 Acute confusion 1. Patient aged ≥65 years
2. Use of two or more agents with anticholinergic activity
OR use of an agent with high anticholinergic activity
Level III53 2
14 Acute confusion 1. Patient aged ≥65 years
2. Use of multiple psychotropic medications (eg,
benzodiazepines, tricyclic antidepressants)

































modified for this study
Newly
developed
15 Serotonin toxicity Use of duloxetine, fentanyl, tramadol, SSRIs, TCAs or
venlafaxine concurrently with MAOI or moclobemide, or
within 14 days of stopping MAOI
Level III54 25




17 Asthma or COPD 1. History of asthma or COPD
2. Use of a β-blocker eye drops for glaucoma
Level I55 8 13
18 Asthma 1. History of asthma
2. Use of SABA more than 3 times/week or use of LABA
3. No use of inhaled corticosteroids
Level I32 Asthma only, Australian
guideline specific7–9
19 COPD 1. Moderate to severe COPD with frequent exacerbation
2. Use of long-acting β-agonist or anticholinergic
3. No use of inhaled corticosteroids
Level I31 COPD only, Australian
guideline specific7–9
20 Asthma or COPD 1. History of asthma or COPD
2. No contraindication to influenza vaccine
3. No influenza vaccination in the previous year
Level I31 32 31 32
21 Influenza-related
pneumonia
1. Patient aged ≥65
2. No contraindication to influenza vaccine
3. No influenza vaccine in the previous year
Level I56 57 2
22 Pneumococcal
pneumonia or sepsis
1. Patient aged ≥65
2. No contraindication to pneumococcal vaccine
3. No pneumococcal vaccine in the previous 6 years
Level III57 58 2
GI indicators
23 GI bleed, perforation or
ulcer or gastritis
1. History of GI ulcer or bleeding
2. NSAID use for at least 1 month
3. No use of gastroprotective agent (eg, PPI)
Level II36 59 Added gastroprotective
agent6 7 13
24 Chronic constipation or
impaction
1. Use of two or more agents with low-to-moderate
anticholinergic activity; OR use of a highly anticholinergic
agent
Level 160 2
25 Chronic constipation or
impaction
1. Regular use of a strong opioid analgesic (fentanyl,
oxycodone, morphine)
2. No concurrent use of a laxative
Level I61 8
26 GI ulcer 1. Patient with dyspepsia
2. PPI not prescribed
Level I62 25
27 GI ulcer 1. Patient with a positive test for Helicobacter pylori
2. Not prescribed H pylori eradication therapy
Level I63 25
28 GI ulcer or bleed 1. Patient with osteoarthritis





1. History of oesophageal disorders (active oesophagitis,
oesophageal ulceration, stricture or achalasia)






































30a Osteoporosis or fracture 1. Use of systemic corticosteroids for at least 3 months
2. No osteoporosis prophylaxis (women: no use of HRT,
bisphosphonate, teriparatide, selective oestrogen receptor
modulators or strontium; men: no use of bisphosphonate
or teriparatide)
Level I66 Removed dose8 13
30b Osteoporosis or fracture 1. This indicator is the same as above, but for male patients Level I66 Removed dose8 13
31 Fracture 1. Female patient
2. History of osteoporosis or fracture
3. No use of HRT, bisphosphonate, teriparatide, selective
oestrogen receptor modulators or strontium
Level I35 Changed from history
of fall6
32 Fracture 1. Male patient
2. History of osteoporosis or fracture
3. No use of bisphosphonate or teriparatide
Level II35 Changed from history
of fall2
33 Fracture 1. Patient aged ≥65 years
2. History of osteoporosis
3. Patient not receiving adequate levels of calcium and
vitamin D
Level III35 2
34 Fracture 1. Patient on high dose inhaled corticosteroid (≥400 μg
fluticasone daily or equivalent) for more than 1 year
2. Bone mineral density not measured in the previous
24 months
Level II35 25
35 Fracture 1. Patient aged ≥65 years
2. Use of a falls-risk medicine (eg, long-acting hypnotic or
anxiolytic, tricyclic antidepressant)
Level I67 Included all falls-risk
medicines6–8
36 Arrhythmia 1. Concurrent use of calcitriol with digoxin
2. Calcium concentration not monitored in the previous
3 months
Level III68 25
37 Hypercalcaemia 1. Use of calcitriol




38 Renal failure or
nephropathy
1. History of diabetes
2. Microalbuminuria and plasma creatinine not monitored in
the previous 12 months





39 Renal failure 1. NSAID use for >3 months
2. Serum creatinine not monitored in the previous 12 months
Level II36 Changed monitoring from 3
to 12 months6 8
40 Renal failure 1. Use of lithium
2. Serum creatinine not monitored in previous 6 months
Level III38 6 7
41 Urinary retention 1. History of BPH
2. Use of an anticholinergic agent

































modified for this study
Newly
developed
42 Urinary retention 1. Use of two or more agents with anticholinergic activity OR
use of a highly anticholinergic agent




1. Use of an oral hypoglycaemic agent
2. HbA1c level not monitored in the previous 6 months
Level I34 Added hypoglycaemia
as outcome2 6
44 Hypoglycaemia 1. Use of a long-acting oral hypoglycaemic agent
(glibenclamide or glimepiride)
2. HbA1c level not monitored in the previous 6 months
Level I34 Added HbA1c monitoring2
45 Hyperglycaemia or
hypoglycaemia
1. Use of insulin




1. Use of insulin or oral hypoglycaemic medicines
2. Use of medicines that may increase or decrease blood
glucose concentration
3. HbA1c level not monitored in the previous 6 months
Level I33 33
47 Hypoglycaemia 1. Use of glibenclamide or glimepiride
2. Renal function not monitored in the previous year
Level II33 33
48 Cardiovascular disease 1. History of diabetes
2. Not on lipid lowering drug
Level II71 71
ARB, angiotensin receptor blocker; BPH, benign prostatic hyperplasia; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; HbA1c, glycated
haemoglobin; HRT, hormone replacement therapy; IHD, ischemic heart disease; LABA, long-acting β agonist; MAOI, monoamine oxidase inhibitor; MI, myocardial infarction; NSAID,
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setting and 21 were newly developed. These were then
sent to the expert clinical panel for full validation and
were independently assessed by 78 expert clinicians
(22.2% response rate). Of the respondents, 32% were
medical physicians and 68% were pharmacists.
The expert panel considered 29 of these (60.4%) to
be sufficiently valid based on the a priori developed cri-
teria (table 2). The majority of these (72.4%, n=21)
were based on level I evidence. A total of 11 cardiovascu-
lar indicators were developed, of which 5 (45.5%) were
validated by the expert clinical panel; four of the five
were based on level I evidence. Of the five mental
health indicators developed, only one had level I evi-
dence and none were validated by the expert panel. Six
respiratory indicators were developed and five of these
were validated, 80% of these were based on level I evi-
dence. A total of seven gastrointestinal indicators, six of
which were based on level I evidence were developed
and five (71.4%) were validated. Of eight osteoporosis/
fracture indicators, half of which were based on level I
evidence and five (62.5%) were validated. Only two of
the five developed renal indicators were validated, with
the level of evidence being level II or less for these.
Finally, six diabetes indicators were developed, four of
which were based on level I evidence and all were vali-
dated by the clinical panel.
DISCUSSION
This study provides a set of face and content validated
indicators of medication-related potentially preventable
hospitalisations, specific for the Australian healthcare
setting linking suboptimal processes of care and medi-
cation use with subsequent hospitalisation. Of a poten-
tial 48 developed indicators, 29 achieved consensus
validation by the expert clinical panel and over 70% of
these were based on level I evidence. An important
feature of these developed indicators is that they are
evidence based, systematically combining evidence-
based recommendations from clinical guidelines with
expert clinical opinion. In addition, these indicators
focus on those chronic conditions which are included
in Australia’s National Health Priority Areas20 or those
that are associated with high disease burden in
Australia.21 41
For each of the six disease clusters for which indica-
tors were developed, the proportion validated by our
expert panel ranged from only 20% (1/5) for the
mental health indicators to 100% for the diabetes indi-
cators (6/6). Interestingly, the level of evidence available
for the metal health indicators around medicine use
and processes of care was minimal (four of the five indi-
cators had only level III evidence), by comparison to the
diabetes indicators where the majority of evidence was
level I.
The health conditions for which these indicators were
developed significantly contribute to the burden of
illness, social and financial costs in Australia, and
prevention of hospitalisations associated with these con-
ditions will provide significant gains in the health of
Australia’s population.20 Furthermore, given the high
prevalence of medication-related hospitalisations in
Australia, identification of areas where medication man-
agement could be improved, particularly at the primary
care level, may also lead to fewer hospitalisations. An
estimated 90 000 hospital admissions annually are con-
sidered to be potentially preventable mediation-related
admissions in those aged 65 years and older.11 Based on
the average cost of hospitalisation in Australia in 2010–
2011 to be $A5400,43 these unnecessary hospitalisations
cost Australia’s healthcare system $A480 million
annually.
Analysis of the developed indicators in a population-
based sample is required to establish operational validity,
and this will be the focus of the next phase of this
research. With the advent of computerised administra-
tive health databases, these indicators have been devel-
oped with the potential to be analysed in such databases
at the population level. Importantly, the characteristics
of those patients’ most vulnerable to mediation-related
hospitalisations will also facilitate the identification of
risk-factors associated with suboptimal medication man-
agement. Implementation of these indicators within
routine monitoring of the Australian healthcare system
will serve to highlight those conditions where hospitalisa-
tions could potentially be avoided through improved
medication management, identify areas of current prac-
tice that may be suboptimal or evidence-practice gaps
and facilitate the development of specific interventions
to improve healthcare and subsequent patient
outcomes.
The standard RAND appropriateness method employs
two rounds; in the first round experts rate indicators
independently and in the second round, experts meet
face to face to discuss the indicators and rate the indica-
tors again, based on the face-to-face discussion.17 Our
study used a modified RAND appropriateness method,
with one round of independent expert panel review,
and subsequent inclusion of indicators which met a
priori defined criteria but no face-to-face meeting of
experts. This is a potential limitation of our study,
because the face-to-face meeting provides an opportun-
ity to discuss indicators with low levels of agreement
between experts, and can identify whether this is due to
true clinical disagreement or simply an issue with the
wording of the indicator.44 It may be that for some indi-
cators true consensus was not achieved if those who dis-
agreed were strongly opposed to the indicator, and this
type of issue may have been identified at a face-to-face
meeting. Despite these limitations, the online survey
technique used in our study eliminates any potential
bias from dominant individuals who may be associated
with face-to-face panel settings.44 This allows for expert
clinical panel members to express their opinions in an
anonymous manner but also gives them time to consider
each of the four elements of preventability together with
8 Caughey GE, Kalisch Ellett LM, Wong TY. BMJ Open 2014;4:e004625. doi:10.1136/bmjopen-2013-004625
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process of care? (%)
Know how to change
the process of care to
reduce the likelihood
of hospitalisation? (%)
Be able to change the






1. History of MI (in 2 years prior to
admission)
2. Not on aspirin, β-blocker, ACEI
or ARB and statin (in 3 months
prior to admission)
Y 71.5 74 79 74 63
2 Acute coronary
syndrome
1. Patient has coronary artery stent
(in 1 years prior to admission)
2. No use of aspirin or clopidogrel
(in 12 months prior to
admission)
Y 75 78 72 72 78
3 CHF 1. History of CHF (in 2 years prior
to admission)
2. Not on an ACEI or ARB (in
3 months prior to admission)
Y 72.5 80 70 70 70
4 CHF 1. History of CHF (in 2 years prior
to admission)
2. Not on a heart failure indicated
β-blocker (in 3 months prior to
admission)
N 63 68 63 63 58
5 CHF 1. History of CHF
2. Use of rosiglitazone or
pioglitazone (in 6 months prior
to admission)
N 38 35 29 47 41
6 CHF 1. History of CHF
2. Use of NSAID (in 3 months prior
to admission)
N 54.5 56 56 50 56
7 CHF or cardiac
ischaemic event
1. History of IHD (in 2 years prior
to admission)
2. Use of rosiglitazone (in
6 months prior to admission)
N 36 33 28 44 39
8 CHF and/or heart
block
1. History of CHF with heart block
or advanced bradycardia (in
2 years prior to admission)
2. Use of digoxin (in 6 months
prior to admission)
Y 75 80 85 75 60
9 CHF or MI 1. Concurrent use of insulin and
rosiglitazone









































process of care? (%)
Know how to change
the process of care to
reduce the likelihood
of hospitalisation? (%)
Be able to change the
process of care to
reduce the likelihood
of hospitalisation? (%)
10 Ischaemic stroke 1. History of chronic AF or
ischaemic stroke (in 2 years
prior to admission)
2. No use of warfarin or aspirin (in
3 months prior to admission)
Y 94.8 100 100 95 84
11 VTE or stroke 1. History of coronary artery
disease or VTE
2. Use of raloxifene
N 54.8 56 50 63 50
Mental health indicators
12 Bipolar disorder 1. History of bipolar disorder
2. Use of lithium
3. 3) Drug level not monitored in
the previous 3 months
N 69 69 63 75 69
13 Acute confusion 1. Patient aged ≥65 years
2. Use of 2 or more agents with
anticholinergic activity OR use
of an agent with high
anticholinergic activity
N 53.5 44 44 63 63
14 Acute confusion 1. Patient aged ≥65 years




N 42.6 69 50 56 38
15 Serotonin toxicity 1. Use of duloxetine, fentanyl,
tramadol, SSRIs, TCAs, or
venlafaxine concurrently with
MAOI or moclobemide, or within
14 days of stopping MAOI
N 53 50 50 56 56
16 Serotonin toxicity 1. Concurrent treatment with strong
CYP1A2 inhibitors (eg,
duloxetine) with fluvoxamine
N 59.5 63 56 63 56
Respiratory indicators
17 Asthma or COPD 1. History of asthma or COPD
2. Use of a β-blocker eye drops for
glaucoma
N 51.2 50 45 50 60
18 Asthma 1. History of asthma
2. Use of SABA more than 3
times/week or use of LABA
3. No use of inhaled
corticosteroids









































process of care? (%)
Know how to change
the process of care to
reduce the likelihood
of hospitalisation? (%)
Be able to change the
process of care to
reduce the likelihood
of hospitalisation? (%)
19 COPD 1. Moderate-to-severe COPD with
frequent exacerbation
2. Use of long-acting β-agonist or
anticholinergic
3. No use of inhaled
corticosteroids
Y 90 90 75 100 95
20 Asthma or COPD 1. History of asthma or COPD
2. No contraindication to influenza
vaccine
3. No influenza vaccination in the
previous year
Y 82.5 80 75 90 85
21 Influenza-related
pneumonia
1. Patient aged ≥65 years
2. No contraindication to influenza
vaccine
3. No influenza vaccine in the
previous year




1. Patient aged ≥65 years
2. No contraindication to
pneumococcal vaccine
3. No pneumococcal vaccine in
the previous 6 years





1. History of GI ulcer or bleeding
2. NSAID use for at least 1 month
3. 3) No use of gastroprotective
agent (eg, PPI)




1. Use of 2 or more agents with
low-to-moderate anticholinergic
activity; OR use of a highly
anticholinergic agent




1. Regular use of a strong opioid
analgesic (fentanyl, oxycodone,
morphine)
2. No concurrent use of a laxative
Y 91 95 79 95 95
26 GI ulcer 1. Patient with dyspepsia
2. PPI not prescribed
Y 74.8 89 58 84 68
27 GI ulcer 1. Patient with a positive test for
Helicobacter pylori
2. Not prescribed H pylori
eradication therapy (PPI twice
daily, clarithromycin 500 mg
twice daily and amoxycillin 1 g
twice daily for 7 days; OR PPI









































process of care? (%)
Know how to change
the process of care to
reduce the likelihood
of hospitalisation? (%)
Be able to change the




500 mg twice daily and
metronidazole 400 mg twice
daily for 7 days; PPI twice daily,
amoxycillin 500 mg three times
a day and metronidazole
400 mg three times a day for
14 days)
28 GI ulcer or bleed 1. Patient with osteoarthritis
2. Dispensed long-term NSAIDs
(including COX-2) therapy









2. Use of alendronate




1. Use of systemic corticosteroids
for at least 3 months
2. No osteoporosis prophylaxis
(women: no use of HRT,
bisphosphonate, teriparatide,
selective oestrogen receptor
modulators or strontium; men:
no use of bisphosphonate or
teriparatide)
Y 80.8 91 86 82 64
31 Fracture 1. Female patient
2. History of osteoporosis or
fracture




Y 81.8 95 82 86 64
32 Fracture 1. Male patient
2. History of osteoporosis or
fracture
3. No use of bisphosphonate or
teriparatide
Y 72.8 82 68 77 64
33 Fracture 1. Patient aged ≥65 years
2. History of osteoporosis
3. Patient not receiving adequate
levels of calcium and vitamin D









































process of care? (%)
Know how to change
the process of care to
reduce the likelihood
of hospitalisation? (%)
Be able to change the
process of care to
reduce the likelihood
of hospitalisation? (%)
34 Fracture 1. Patient on high dose inhaled
corticosteroid (≥400 μg
fluticasone daily or equivalent)
for more than 1 year
2. Bone mineral density not
measured in the previous
24 months
N 40.8 45 32 45 41
35 Fracture 1. Patient aged ≥65 years




Y 71.5 82 77 68 59%
36 Arrhythmia 1. Concurrent use of calcitriol with
digoxin
2. Calcium concentration not
monitored in the previous
3 months
N 31.5 18 18 45 45
37 Hypercalcaemia 1. Use of calcitriol
2. Plasma calcium concentration
not monitored in the previous
3 months
N 62.8 73 55 64 59
Renal indicators
38 Renal failure or
nephropathy
1. History of diabetes
2. Microalbuminuria and plasma
creatinine not monitored in the
previous 12 months
3. Patient not on ACEI or ARB
Y 79.3 88 65 82 82
39 Renal failure 1. NSAID use for >3 months
2. Serum creatinine not monitored
in the previous 12 months
Y 79 76 76 88 76
40 Renal failure 1. Use of lithium
2. Serum creatinine not monitored
in the previous 3 months
N 66.5 65 65 65 71
41 Urinary retention 1. History of BPH
2. Use of an anticholinergic agent
N 59 59 65 59 53
42 Urinary retention 1. Use of 2 or more agents with
anticholinergic activity OR use
of a highly anticholinergic agent




1. Use of an oral hypoglycaemic
agent
2. HbA1c level not monitored in
the previous 6 months









































process of care? (%)
Know how to change
the process of care to
reduce the likelihood
of hospitalisation? (%)
Be able to change the
process of care to
reduce the likelihood
of hospitalisation? (%)
44 Hypoglycaemia 1. Use of a long-acting oral
hypoglycaemic agent
(glibenclamide or glimepiride)
2. HbA1c level not monitored in
the previous 6 months
Y 95 100 90 95 95
45 Hyperglycaemia or
hypoglycaemia
1. Use of insulin
2. HbA1c level not monitored in
the previous 6 months
Y 91.5 100 95 90 81
46 Hyperglycaemia or
hypoglycaemia
1. Use of insulin or oral
hypoglycaemic medicines
2. Use of medicines that may
increase or decrease blood
glucose concentration
3. HbA1c level not monitored in
the previous 6 months
Y 76.8 88 75 75 69
47 Hypoglycaemia 1. Use of glibenclamide or
glimepiride
2. Renal function not monitored in
the previous year
Y 81.5 75 75 88 88
48 Cardiovascular
disease
1. History of diabetes
2. Not on lipid lowering drug
Y 81.8 88 88 88 63
Numbers in bold represent those who achieved an average score of ≥70% agreement by the expert panel.
*Percentage of respondents who answered ‘Agree’ or ‘Yes’ on the three-point Likert scale.
AF, atrial fibrillation; ARB, angiotensin receptor blocker; BPH, benign prostatic hyperplasia; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal;
HbA1c, glycated haemoglobin; IHD, ischemic heart disease; LABA, long-acting β agonist; MAOI, monoamine oxidase inhibitor; MI, myocardial infarction; NSAID, non-steroidal anti-inflammatory
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the supporting evidence base of each developed indica-
tor. In addition, our method for developing the indica-
tors systematically combined the available evidence base
with the opinion of clinical experts to develop indicators
that are both face and content valid.19 The modified
RAND method used in our study has been used in indi-
cator development studies previously.18 45 A recent
Australian study used this method to validate 657 indica-
tors of healthcare appropriateness.16
Our study achieved a 22% response rate, which is
lower than other Australian studies involving medical
practitioners, which typically achieve a response rate of
around 30%.46–48 While this may limit the generalisabil-
ity of our findings, our results are strengthened by
having medical specialists, general practitioners and
pharmacists on the expert review panel.44 In addition,
78 expert clinicians reviewed the clinical indicators for
our study; by comparison, previous studies which devel-
oped clinical indicators for preventable medication-
related hospitalisation used fewer than 20 expert
reviewers.
In conclusion, this study has developed a set of face
and content validated indicators of medication-related
potentially preventable hospitalisations specific for the
Australian healthcare setting, linking medication use
with suboptimal processes of care resulting in adverse
outcomes of hospitalisations. As a measure of health
system performance these indicators could identify areas
of sub-optimal medication management, particularly at
the primary care level, based on routinely collected
health administrative health data but with the strong
focus on patient outcomes and quality of care rather
than processes or quantity.
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